Foreign patent attorneys entering the Indian national phase often assume that prosecution will broadly follow USPTO or EPO patterns. In practice, it does not. Indian examination is structured differently, procedurally compressed, and driven closely by statutory language. Many otherwise strong applications encounter difficulty not because of the underlying invention, but because they are prosecuted using assumptions drawn from other jurisdictions.
The First Examination Report is not a preliminary exchange. In most cases, it is the decisive stage of prosecution. How the application is positioned before the report is issued often determines how much room remains for amendment later.
Examination begins only after a Request for Examination is filed. In PCT national phase cases, this is typically done at entry. The First Examination Report is generally issued within six to eighteen months from that request, depending on the technical field and examination group. Software and biotechnology cases tend to attract closer scrutiny, particularly where eligibility or inventive step concerns are apparent on the face of the claims.
Unlike US Office Actions or EPO communications, the Indian First Examination Report consolidates all objections into a single document. Formal and substantive issues are raised together. Drafting deficiencies are treated seriously. Objections may relate to lack of antecedent basis, unclear terminology, insufficient support in the description, improper Markush structuring, or sequence listing inconsistencies. These are not merely clerical concerns. They can influence claim interpretation and indirectly affect amendment flexibility.
Eligibility objections under Section 3 of the Patents Act frequently form the core of the report. India applies statutory exclusions directly. The analysis does not mirror the US approach under section 101, nor does it follow the EPO’s technical effect framework. Claims directed to computer-related inventions, medical treatment methods, discoveries of natural substances, certain pharmaceutical inventions, or plant and animal subject matter are examined within the statutory exclusions. It is not uncommon for claims allowed elsewhere to face rejection in India on this basis. Arguments must therefore be framed within the statutory structure rather than by reference to foreign allowances.
Inventive step analysis in India is often closer in style to European reasoning, but examiners commonly combine multiple prior art documents. The approach can be assertive. Where the specification does not clearly articulate the technical problem and the advancement achieved, inventive step objections can be difficult to overcome, particularly once amendment limits are considered.
The response period to the First Examination Report is six months from issuance, extendable by three months. There is no further extension, no RCE practice, and no continuation mechanism in the US sense. If objections are not resolved within this window, the application is deemed abandoned. From a portfolio management perspective, this compressed timeline requires coordinated review and instructions early in the process.
Amendment practice under Section 59 is applied strictly. Amendments must be clearly supported by the specification as originally filed. Attempts to introduce intermediate generalisations, reassemble claim combinations not originally presented, or rely on technical effects not expressly described are often refused. Narrowing to specific disclosed embodiments, combining dependent claims as drafted, or restricting numerical ranges is generally acceptable. The key constraint is that the amendment must be traceable to the original disclosure without reconstruction. Applications drafted primarily for US flexibility can encounter difficulty at this stage if fallback positions were not expressly included.
Hearings are available but should not be viewed as equivalent to examiner interviews in the United States. They do not function as exploratory discussions. They address issues already on record. A hearing rarely compensates for an inadequately structured written response.
In practice, the First Examination Report should be approached as the principal opportunity to resolve eligibility, novelty, and inventive step issues in a structured manner. A considered response addresses statutory eligibility directly, refines the claim set within supported boundaries, and articulates technical advancement over cited art in clear terms. Partial or minimal responses often result in further reports and additional pressure on the statutory timeline.
The most significant strategic advantage in Indian prosecution arises before national phase entry. At that stage, foreign counsel can evaluate whether the specification contains explicit fallback embodiments, whether computer-related claims include sufficient technical structure, and whether pharmaceutical disclosures provide adequate support for narrower claim positions. Once the First Examination Report is issued, the room for structural correction is materially reduced.
Indian examination is disclosure-driven and statute-based. It offers limited procedural flexibility and a narrow amendment corridor. Applications prepared with these constraints in mind tend to proceed efficiently. Those adjusted only after objections are raised frequently lose scope or face abandonment.
Understanding this framework is essential for effective patent protection in India.
For foreign patent attorneys managing international portfolios, working with a registered Indian patent agent early helps address translation accuracy, amendment support requirements, and examination strategy before issues arise during prosecution.
Origiin IP Solutions LLP supports overseas law firms with Indian PCT national phase entry, FER responses, hearings, and coordinated portfolio handling across jurisdictions.
For assistance with India national phase filings and prosecution support:
https://origiin.com/contact-us/
To understand the Indian national phase procedure in detail:
https://origiin.com/pct-national-phase-entry-india/
